Question 1

What is Innovent Biologics?

Accepted Answer

Innovent Biologics is a Company.

Question 2

How often does Innovent Biologics appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 15 articles.

Question 3

When was Innovent Biologics first tracked by Ergen?

Accepted Answer

First tracked on May 08, 2026.

Question 4

When was Innovent Biologics last mentioned in news?

Accepted Answer

Last active on Jun 01, 2026.

Question 5

What is Innovent Biologics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 38 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Innovent Biologics in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Innovent Biologics?

Accepted Answer

IBI363 Shows Survival Benefits in NSCLC (May 21, 2026, 9 articles).

Question 8

How did the "IBI363 Shows Survival Benefits in NSCLC" event impact Innovent Biologics?

Accepted Answer

Innovent Biologics is the developer and co-commercializer of IBI363, and the positive long-term clinical trial results enhance its product pipeline and market position in oncology. The company's stock performance is likely to benefit from these favorable outcomes and the progression to global Phase 3 studies.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.